Audit: QRS - Plasmalogens for Health & Longevity
Audit conducted on 22/09/2026 19:28 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values, time-to-effect figures, benefit/risk items, contraindications, interactions, biomarker targets and qualitative items trace to ER lines 283-299, 314-318, 350, 372-391. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No established target; track change from own baseline” mirrors ER lines 374-375, 381; speculative tiers carry the ER’s own hedged headings. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute; at-a-glance keeps “whether that changes anything remains open” in line with ER line 409. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from ER lines 294-298; Key Interactions only from ER lines 283-290; risks only from the ER Potential Risks & Side Effects section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, brand names or expert names appear anywhere in the QRS; Fujino and the Institute of Rheological Functions of Food were correctly dropped from action_1_sub. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only generic ER-sourced references (“the athlete mood trial”, “a completed Japanese trial”) are used, both verbatim ER phrasings. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, hedged register matching the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents dose, timing, markers and the open question without either hype or discouragement. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Targets and cadence are presented as measurements, not orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions in the QRS voice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “should”, “recommend”, “advise” or “guidance” in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the Monitoring table, where they are the marker names themselves. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefit and risk tiers are collapsed to semicolon-separated key facts; gate items carry no rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Nine-marker panel, 12-week retest cadence and a source-quality-aware protocol address exactly this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Specialist lipidomics markers and split dosing with meals are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification down to a general-population “just take a capsule” framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance foregrounds target engagement versus unproven outcome, the distinction that matters to a self-tracking user. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears only in the ER-derived title; “anti-aging” appears nowhere. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | The lede uses “Oral doses raise blood levels reliably”, not the ER Conclusion’s “swallowed plasmalogens”; no “pill”, “shot” or “by mouth” anywhere. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings match the template byte-for-byte (lines 446, 491, 538, 570, 587, 616, 645, 649-651, 806). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names present; marker_#_* expanded to 9 rows and qualitative_item_# to 6 items as the template’s # notation intends. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows the head, full stylesheet, website="evidence_review", website="audit", website="full_review" spans and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds a QRS element is empty; the High benefit/risk tiers carry explanatory ER text and are handled under 12.5 / 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3 labels reproduce the ER bold labels at lines 314, 315, 317 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol, time-to-effect, marker and tier labels all map to ER wording. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan returns no emoji; the ER’s “⚠️ Conflicted” marker was correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the template budget: gate items stripped of rationale, benefit/risk tiers collapsed to single lines, marker targets and “why” cells trimmed. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after <!doctype html> at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: plasmalogens_2026-0823-1647_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22, matching QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1903. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual filename plasmalogens_2026-0823-1647_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed across all nine keys including git_user and git_issue. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Plasmalogens for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Plasmalogens for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/22/2026” from 2026-0922-1903. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header is the template subline only; the ER’s nine alternate names are not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “a structural fat class that human cells make in large amounts, sold as a supplement from scallop, sea squirt, chicken or laboratory sources for memory and metabolic health” before any verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 409-411 into what is settled (level rise, tolerability) versus what is not. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 69 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Source species from ER line 340; age decline and mortality/cardiometabolic association from line 409; level rise and tolerability from line 411. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “ether phospholipid”, “PlsEtn” and “ferroptosis” are all avoided in favour of plain terms. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial named, no year, no sample size. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No hazard ratios, confidence intervals or point estimates. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from “Populations who should avoid Plasmalogens” at ER lines 294-298. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements at lines 573-582. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales such as “until the ether-lipid and tumour-metabolism question is resolved” and “since no trial has enrolled them” are stripped; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Full ferritin and transferrin-saturation thresholds preserved (lines 577-578); the marine-source restriction preserved as “(marine-derived products)”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s only “>” usages are self-interpreting numeric thresholds with units, not ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations and the section is populated accordingly. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map to ER lines 283-290. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets present; no overlap with the five contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements at lines 590-606. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale (“which add omega-3 fats that mildly inhibit platelet function”) and mitigation detail are stripped; the ER’s “Other interventions — “ prefix on the dietary-pattern bullet is removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drug lists preserved for anticoagulants, ferroptosis inducers, antioxidants and NSAIDs; the “gram-dose marine-oil preparations” scope qualifier is retained on item 1. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets contain no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists eight such interactions and the section is populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells map to ER Therapeutic Protocol lines 314, 315 and 317. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard 1 mg trial dose, the 2 mg mood regimen, and the 4 g alkylglycerol precursor route — the three dosing regimens with human data. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol provides well more than three actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-derived content (lines 450-486); no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Mood/fatigue, memory and blood plasmalogen level — the three aspects named in ER line 350. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Mood and fatigue (Medium tier) → memory (Low tier) → blood plasmalogen level (Speculative tier), correct descending order. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three or more time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated from ER line 350 (lines 497-530). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet at line 350. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items map to ER headings at lines 145, 151, 157, 165, 171, 177, 183, 191, 195, 199, 203. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 540, 543, 550, 557. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of ER benefit headings only; no magnitudes, funding notes or study descriptions carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High benefit (line 141); benefits_high carries style="display: none" at line 540 with an empty label. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items map to ER headings at lines 229, 237, 245, 249, 253, 257, 261, 265. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 618, 621, 626, 632. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The 18% decline figure, the 56-participant PPI-1011 detail and the retraction note are all correctly omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High risk (line 225); risks_high carries style="display: none" at line 618. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows map one-to-one to the ER Monitoring Protocol & Defining Success table at lines 372-382. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present: PlsEtn, erythrocyte plasmalogen, Omega-3 Index, hs-CRP, fasting triglycerides, ferritin, HbA1c, cognitive battery, liver enzymes. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 795-800 condense ER lines 368 and 370, including the baseline double-run of the cognitive battery and the 3-month red-cell caveat. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items map to the ER’s “Qualitative markers worth tracking alongside the labs” list at lines 386-391. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present and unaltered (lines 809-837). |
Issues 22/09/2026 19:28
Pass rate 100.00%. No issues found.
Issues 22/09/2026 19:20
- 10.2 — Timing chosen over precursor regimen:
action_3(line 477) uses “Timing of day”, but the ER’sTherapeutic Protocoloffers two distinct precursor regimens with explicit doses — shark liver oil at 4 g/day and the synthetic alkylglycerol at 900–3,600 mg/day — which carry the ER’s Medium-graded lipid/inflammation benefit and its Medium-graded gastrointestinal risk; timing is already covered insideaction_1_sub(“split into two doses with meals”).
Fixes 22/09/2026 19:20
- 10.2 — Precursor regimen replaces timing cell: Replaced the third protocol cell “Timing of day / Morning and evening, with food” with the ER’s “Precursor approach (shark liver oil) / 4 g daily”, sub-line “Purified alkylglycerols for three weeks; the cheapest precursor route, but it carries a shark-fishery sourcing problem.” The panel now carries a third distinct actionable regimen, and dosing with meals remains stated in
action_1_sub.
Issues 22/09/2026 19:11
- 1.3 — Tolerability claim generalised: [at_a_glance] (lines 437-438) says oral doses “are well tolerated” without a duration limit, while the ER Conclusion (line 411) states only that “short courses have been well tolerated” and notes that “long-term use has never been studied” (line 413).
Fixes 22/09/2026 19:11
- 1.3 — Tolerability claim scoped to short courses: Changed [at_a_glance] from “Oral doses raise blood levels reliably and are well tolerated” to “Oral doses raise blood levels reliably and short courses are well tolerated”, restoring the ER Conclusion’s duration limit. The lede remains within the 70-word budget at 69 words.
Issues 22/09/2026 19:07
- 12.3 / 12.4 — Parenthetical qualifier not stripped: The Low benefit item at QRS line 552 reads “Memory performance in adults with subjective forgetfulness (conflicted)”; the parenthetical qualifier, carried over from the ER’s “⚠️ Conflicted” marker, must be stripped since the tier already encodes evidence strength.
Fixes 22/09/2026 19:07
- 12.3 / 12.4 — Parenthetical qualifier stripped: Removed “(conflicted)” from the Low benefit item, so it now reads “Memory performance in adults with subjective forgetfulness; non-motor symptoms in Parkinson’s disease; …”.